GO:0072675 osteoclast fusion: Multinucleation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072675 osteoclast fusion is the plasma membrane fusion process that converts mononuclear osteoclast precursors into multinucleated bone-resorbing osteoclasts.
• Fusion is a late, distinct step in osteoclastogenesis, regulated separately from differentiation and survival, and it determines osteoclast size, multinuclearity, and resorptive capacity.
• Key molecular players include Moesin, caspase-8, scramblases, BAR proteins, SNX10, and endogenous collagenases, which control membrane apposition, lipid scrambling, and cytoskeletal remodeling.
• Dysregulated osteoclast fusion contributes to bone diseases such as osteoporosis, inflammatory bone loss, and periprosthetic osteolysis, and influences drug sensitivity of osteoclasts.
• Osteoclast fusion is experimentally tractable using knockout, point-mutation, knock-in, and overexpression models in RAW264.7 and primary bone marrow macrophages.
• CRISPR-based screens and bioinformatics can identify novel fusion regulators, complementing classical osteoclast differentiation assays.
Description
Osteoclasts are the sole bone-resorbing cells in the body, and their function depends on their unique multinucleated state. The Gene Ontology term GO:0072675, osteoclast fusion, describes the plasma membrane fusion process that results in fusion of mononuclear osteoclasts to form a multinuclear osteoclast. This process is a late and distinct step in osteoclastogenesis, following proliferation, differentiation, and commitment of monocyte/macrophage precursors. Fusion is not merely a morphological endpoint; it is a regulated event that determines osteoclast size, nuclear number, and resorptive efficiency, and it is controlled by a dedicated molecular machinery. Researchers study osteoclast fusion because it represents a point of vulnerability in bone disease. Multinucleation is required for efficient bone resorption, and perturbations in fusion alter osteoclast function and drug sensitivity. The fusion process involves cell-cell recognition, membrane apposition, lipid redistribution, and cytoskeletal reorganization, with proteins such as Moesin, caspase-8, scramblases, BAR proteins, SNX10, and collagenases playing defined roles. Understanding these mechanisms provides opportunities for therapeutic intervention in osteoporosis, inflammatory bone loss, and other osteoclast-driven pathologies. This article integrates the QuickGO definition of GO:0072675 with verified PubMed literature to provide a research-grade overview of osteoclast fusion, its molecular regulators, disease relevance, and experimental approaches. It is intended for scientists seeking to design CRISPR-based models, interpret osteoclast phenotypes, or identify novel fusion genes.
osteoclast fusion At A Glance
| GO ID | GO:0072675 |
|---|---|
| GO term | osteoclast fusion |
| Ontology | biological_process |
| Synonym | none |
| Major function | Plasma membrane fusion of mononuclear osteoclasts to form multinuclear osteoclasts |
| Cellular context | Osteoclast lineage; monocyte/macrophage precursors |
| Physiological outcome | Multinucleated, bone-resorbing osteoclast |
| Regulatory examples | Moesin, caspase-8, scramblases, BAR proteins, SNX10, collagenases |
| Disease relevance | Osteoporosis, inflammatory bone loss, osteolysis |
What Is GO:0072675?
GO:0072675 osteoclast fusion is defined as the plasma membrane fusion process that results in fusion of mononuclear osteoclasts to form a multinuclear osteoclast. In other words, it is the cell-cell fusion event by which single-nucleus osteoclast precursors merge their plasma membranes to generate a mature, multinucleated osteoclast. This term captures the fusion step itself, distinct from earlier differentiation and later resorptive activities.
Why Is osteoclast fusion Important in Cell Biology?
Osteoclast fusion is important because multinucleation is a prerequisite for efficient bone resorption, and the fusion process is a regulated step that can be targeted to modulate osteoclast activity. Fusion influences osteoclast size, nuclear number, and drug sensitivity, making it relevant to bone physiology and pathology. Defects in fusion regulators such as SNX10 or Moesin alter osteoclast size and function, demonstrating that fusion is genetically controlled and not a passive event. Consequently, understanding GO:0072675 provides a foundation for developing therapies for osteoporosis, inflammatory bone diseases, and osteolysis.
• Multinucleation is required for efficient bone resorption; fusion determines osteoclast resorptive capacity.
• Fusion is a late, genetically separable step in osteoclastogenesis, distinct from differentiation.
• Moesin controls cell-cell fusion and osteoclast function, linking cytoskeletal regulation to fusion.
• Caspase-8 promotes scramblase-mediated phosphatidylserine exposure, a key step in osteoclast precursor fusion.
• Mechanical cues and membrane-cortex attachment via BAR proteins regulate osteoclast fusion.
• Endogenous collagenases modulate osteoclast fusion, connecting matrix remodeling to multinucleation.
• SNX10 regulates osteoclastogenic cell fusion and osteoclast size in mice.
• Fusion dysregulation contributes to osteoporosis and inflammatory bone loss.
• Osteoclast fusion influences drug sensitivity, with implications for anti-resorptive therapy.
• Fusion regulators are candidate targets for CRISPR-based functional screens.
What Happens During osteoclast fusion?
Commitment and fusion competence of mononuclear precursors
In simple terms: Before cells can fuse, they must become ready to fuse.
Osteoclast fusion occurs after mononuclear precursors have differentiated and acquired fusion competence. This step is regulated separately from earlier differentiation, and the fusion-competent state involves expression of specific fusogenic machinery. Regulators of osteoclast differentiation and cell-cell fusion have been reviewed, highlighting that fusion is a distinct late event.
Membrane apposition and phosphatidylserine exposure
In simple terms: Cells expose a lipid signal that helps their membranes merge.
A critical step in osteoclast fusion is the exposure of phosphatidylserine on the outer leaflet of the plasma membrane, which is promoted by caspase-8 and scramblases. Caspase-8 promotes scramblase-mediated phosphatidylserine exposure and fusion of osteoclast precursors. This lipid redistribution facilitates membrane apposition and fusion pore formation.
Cytoskeletal remodeling and membrane-cortex attachment
In simple terms: The cell's internal skeleton must rearrange for fusion to occur.
Mechanical control of osteoclast fusion involves membrane-cortex attachment and BAR proteins, which regulate cytoskeletal dynamics and membrane curvature. Moesin, an ERM protein, controls cell-cell fusion and osteoclast function, linking the cytoskeleton to fusion. These components coordinate the morphological changes required for membrane merging.
Vesicular trafficking and SNX10 function
In simple terms: Internal sorting proteins help deliver the right components for fusion.
SNX10 regulates osteoclastogenic cell fusion and osteoclast size in mice, indicating a role for endosomal sorting and trafficking in fusion. SNX10 may control the delivery of fusogenic factors or membrane components to the site of fusion.
Extracellular matrix remodeling by collagenases
In simple terms: Enzymes that cut collagen also influence how osteoclasts fuse.
Endogenous collagenases regulate osteoclast fusion, suggesting that matrix remodeling and fusion are coupled. This step may involve cleavage of matrix components or membrane-associated substrates that modulate fusion efficiency.
Key Genes Involved in GO:0072675 osteoclast fusion
The following genes and proteins have been experimentally implicated in osteoclast fusion (GO:0072675) and are commonly studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSN | Moesin controls cell-cell fusion and osteoclast function | Cytoskeletal regulation of fusion |
| CASP8 | Promotes scramblase-mediated phosphatidylserine exposure and fusion | Lipid scrambling and fusion initiation |
| XKR8 | Scramblase candidate downstream of caspase-8 | Phosphatidylserine exposure |
| SNX10 | Regulates osteoclastogenic cell fusion and osteoclast size | Endosomal trafficking in fusion |
| MMP13 | Endogenous collagenase regulating osteoclast fusion | Matrix remodeling and fusion |
| MMP9 | Endogenous collagenase implicated in fusion regulation | Matrix remodeling and fusion |
| BIN1 | BAR protein involved in membrane curvature | Membrane-cortex attachment |
| BIN2 | BAR protein involved in membrane curvature | Membrane-cortex attachment |
| EZR | ERM protein related to Moesin | Cytoskeletal regulation |
| RDX | ERM protein related to Moesin | Cytoskeletal regulation |
| NFATC1 | Master transcription factor of osteoclastogenesis | Upstream regulator of fusion competence |
| DCSTAMP | Fusion-mediating transmembrane protein | Osteoclast fusion machinery |
| OCSTAMP | Fusion-mediating transmembrane protein | Osteoclast fusion machinery |
| ATP6V0D2 | V-ATPase subunit involved in fusion | Osteoclast fusion and acidification |
| CD47 | Membrane protein regulating fusion | Fusion efficiency |
| ITGB3 | Integrin involved in osteoclast function | Adhesion and fusion |
| SRC | Kinase regulating osteoclast cytoskeleton | Fusion and resorption |
How Is osteoclast fusion Regulated?
Osteoclast fusion is regulated at multiple levels. Caspase-8 controls scramblase-mediated phosphatidylserine exposure, a key upstream event for fusion. Moesin and BAR proteins regulate membrane-cortex attachment and cytoskeletal dynamics required for fusion. SNX10 influences fusion and osteoclast size, likely through endosomal trafficking. Endogenous collagenases modulate fusion, linking extracellular matrix remodeling to multinucleation. Physiologically, fusion is heterogeneous and regulated in a manner that affects drug sensitivity. These regulatory inputs ensure that fusion occurs only when appropriate and that osteoclast size is matched to functional demand.
osteoclast fusion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CASP8 | Osteoclast fusion and bone resorption | Knockout in RAW264.7 cells |
| SNX10 | Osteoclast size and bone homeostasis | Knockout mouse and cell models |
| MSN | Osteoclast function and fusion | Knockout and overexpression in osteoclast precursors |
| MMP13 | Matrix remodeling and fusion | Knockout and point-mutation models |
| DCSTAMP | Osteoclast fusion and osteoporosis | Knockout and knock-in models |
Osteoporosis and bone loss
Osteoclast fusion contributes to the formation of multinucleated osteoclasts that resorb bone. Dysregulated fusion can increase osteoclast size and resorptive activity, contributing to osteoporosis and inflammatory bone loss. Targeting fusion regulators may reduce pathological bone resorption.
Inflammatory bone diseases
Inflammatory conditions promote osteoclastogenesis and fusion, leading to bone erosion. Osteoblast-osteoclast cross-talk is a therapeutic target, and microcarriers promoting bone homeostasis repair have been tested in osteoporotic rats. Fusion is a downstream event in this cross-talk.
Periprosthetic osteolysis and implant failure
Osteoclast fusion is central to osteolysis around implants, where multinucleated osteoclasts resorb bone. Understanding fusion mechanisms may inform strategies to prevent implant loosening.
Drug sensitivity and therapeutic implications
Osteoclast heterogeneity and multinucleation influence drug sensitivity, meaning fusion status may affect responses to anti-resorptive therapies. This has implications for personalized treatment of bone diseases.
From osteoclast fusion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for osteoclast fusion? | CRISPR knockout in RAW264.7 or bone marrow macrophages |
| Does a specific point mutation affect fusion? | Point-mutation knock-in via CRISPR |
| Does a fusion protein need a tag for localization? | Tagged knock-in |
| Does overexpression drive fusion? | Overexpression in osteoclast precursors |
| Which genes regulate fusion in a screen? | CRISPR library screening |
| How does a fusion regulator affect bone phenotype? | In vivo knockout mouse models |
How to Study the osteoclast fusion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TRAP staining | Osteoclast differentiation and multinucleation | Fusion quantification |
| Annexin V staining | Phosphatidylserine exposure | Fusion initiation |
| Live-cell imaging | Membrane fusion events | Real-time fusion dynamics |
| Immunofluorescence | Protein localization (Moesin, BAR proteins) | Cytoskeletal role in fusion |
| CRISPR knockout | Gene requirement for fusion | Functional validation |
| CRISPR screen | Genome-wide fusion regulators | Discovery of novel genes |
| RNA-seq | Transcriptional programs | Fusion competence markers |
| Proteomics | Protein interactions in fusion | Mechanistic studies |
Cell-cell fusion assays
Fusion can be quantified by counting multinucleated cells, measuring nuclei per osteoclast, or using fluorescent membrane dyes. These assays are standard for assessing osteoclast fusion in vitro.
Phosphatidylserine exposure detection
Annexin V staining or similar methods detect phosphatidylserine on the outer membrane, a key step in fusion. Caspase-8 and scramblase activity can be assessed in this context.
Live-cell imaging and cytoskeletal analysis
Time-lapse imaging and staining for actin, Moesin, and BAR proteins reveal cytoskeletal dynamics during fusion. These methods show how membrane-cortex attachment changes during fusion.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens can identify novel fusion regulators, and bioinformatics analysis of osteoclast transcriptomes can prioritize candidates. These approaches complement classical assays.
How CRISPR Can Be Used to Study GO:0072675 osteoclast fusion
Knockout
CRISPR knockout of candidate genes such as CASP8 or SNX10 in osteoclast precursors can test whether they are required for fusion. Knockout models have demonstrated roles for caspase-8 in phosphatidylserine exposure and for SNX10 in osteoclast size.
Point Mutation
Point mutations can dissect specific domains or catalytic residues. For example, mutating caspase-8 catalytic activity can test its role in scramblase activation and fusion. Point-mutation models help distinguish fusion-specific functions from other roles.
Knock-in
Knock-in of tagged proteins, such as fluorescently labeled Moesin, allows visualization of fusion machinery dynamics. Knock-in can also introduce disease-associated variants to study their impact on fusion.
Overexpression
Overexpression of fusion regulators like BAR proteins or Moesin can drive or enhance fusion, revealing sufficiency. Overexpression models are useful for gain-of-function studies in osteoclast precursors.
How EDITGENE Supports osteoclast fusion Research
Researchers studying osteoclast fusion-related genes often need to determine whether a candidate gene is causally involved in multinucleation, and to dissect the precise molecular step it controls. EDITGENE provides CRISPR-based cell model services that enable such functional studies in osteoclast precursors and other relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for osteoclast fusion research.
Frequently Asked Questions About osteoclast fusion
What is GO:0072675 osteoclast fusion?
GO:0072675 osteoclast fusion is the plasma membrane fusion process that results in fusion of mononuclear osteoclasts to form a multinuclear osteoclast.
What genes are involved in osteoclast fusion?
Key genes include MSN, CASP8, SNX10, MMP13, MMP9, BIN1, BIN2, DCSTAMP, and OCSTAMP, among others.
How is osteoclast fusion regulated?
It is regulated by caspase-8-mediated phosphatidylserine exposure, Moesin and BAR proteins, SNX10 trafficking, and collagenases.
Why is osteoclast fusion important for bone health?
Multinucleation is required for efficient bone resorption, and fusion determines osteoclast size and function.
What diseases involve osteoclast fusion?
Osteoporosis, inflammatory bone loss, and periprosthetic osteolysis involve dysregulated osteoclast fusion.
How can I study osteoclast fusion in the lab?
Common methods include TRAP staining, Annexin V staining, live-cell imaging, and CRISPR knockout in osteoclast precursors.
What is the role of caspase-8 in osteoclast fusion?
Caspase-8 promotes scramblase-mediated phosphatidylserine exposure, which is required for fusion of osteoclast precursors.
How does SNX10 affect osteoclast fusion?
SNX10 regulates osteoclastogenic cell fusion and osteoclast size in mice.
Can CRISPR be used to study osteoclast fusion?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are used to dissect fusion mechanisms.
What cell models are used for osteoclast fusion research?
RAW264.7 cells and primary bone marrow macrophages are commonly used, along with in vivo mouse models.
Conclusion
GO:0072675 osteoclast fusion is a genetically regulated process that converts mononuclear precursors into multinucleated bone-resorbing osteoclasts. Its molecular machinery includes caspase-8, scramblases, Moesin, BAR proteins, SNX10, and collagenases, which coordinate membrane apposition, lipid scrambling, and cytoskeletal remodeling. Dysregulation of fusion contributes to osteoporosis and inflammatory bone diseases, making it a therapeutic target. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, are powerful tools for dissecting fusion mechanisms and identifying novel regulators. EDITGENE provides these services to accelerate osteoclast fusion research.
References
- 1. Søe K. 2020. Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity-Potential Implications for Drug Sensitivity.. Int J Mol Sci 21(20) PMID: 33086479
- 2. Dufrançais O et al.. 2025. Moesin controls cell-cell fusion and osteoclast function.. J Cell Biol 224(11) PMID: 41143651
- 3. Krishnacoumar B et al.. 2024. Caspase-8 promotes scramblase-mediated phosphatidylserine exposure and fusion of osteoclast precursors.. Bone Res 12(1):40 PMID: 38987568
- 4. Wan Y et al.. 2025. Mechanical control of osteoclast fusion by membrane-cortex attachment and BAR proteins.. J Cell Biol 224(7) PMID: 40338171
- 5. Kim HJ et al.. 2020. Endogenous Collagenases Regulate Osteoclast Fusion.. Biomolecules 10(5) PMID: 32370054
- 6. Zheng J et al.. 2024. Targeting Osteoblast-Osteoclast Cross-Talk Bone Homeostasis Repair Microcarriers Promotes Intervertebral Fusion in Osteoporotic Rats.. Adv Healthc Mater 13(31):e2402117 PMID: 39155412
- 7. Barnea-Zohar M et al.. 2024. SNX10 regulates osteoclastogenic cell fusion and osteoclast size in mice.. J Bone Miner Res 39(10):1503-1517 PMID: 39095084
- 8. Miyamoto T. 2011. Regulators of osteoclast differentiation and cell-cell fusion.. Keio J Med 60(4):101-5 PMID: 22200633
